Jefferies Initiates GRDN at Buy With $44 Target, Stock Surges 9.1%

NEW YORK, March 31 —

Jefferies initiated coverage of Guardian Pharmacy Services (GRDN) at Buy with a $44 price target Monday. Shares jumped 9.1% to close at $37.25, triggering additions to momentum and strong buy watchlists tracked by institutional screeners.

Guardian Pharmacy Services operates in the long-term care pharmacy segment, supplying medications and clinical services to skilled nursing and assisted living facilities. Its revenue is contracted and recurring; facility clients face high switching costs, which shields the business from the margin pressure common in retail pharmacy. The company generated $1.4bn in TTM revenue. At 27.5x forward P/E, the stock trades at a growth premium tied to an aging U.S. population and Guardian's scale in a historically fragmented market. The Jefferies $44 target implies roughly 18% upside from Monday's close. On Wall Street, a Buy initiation from a major bank frequently prompts competing desks to follow with their own coverage — expanding the universe of institutions tracking the stock. GRDN's addition to both 'Best Momentum Stocks' and 'New Strong Buy Stocks' lists after Monday's move signals that algorithmic screeners have already flagged the initiation, adding systematic buying pressure on top of discretionary order flow.

The immediate test is whether GRDN holds above $37 in the two to three weeks following the initiation — that close now serves as near-term technical support. Single-day pops of 9% or more frequently see a retracement test within the first 10 trading sessions. Sustained above-average volume on up days would point to institutional accumulation rather than a short-lived catalyst trade. A second sell-side initiation, particularly from a healthcare-focused desk, would reinforce the Jefferies thesis and likely accelerate the path to the $44 target without requiring a fundamental earnings catalyst. A break below the pre-initiation range on elevated volume, however, would suggest Monday's move was a single-desk event rather than the start of a broader re-rating.

Basis Report has not yet published a full analysis of Guardian Pharmacy Services — generate a GRDN deep-dive at /stock/grdn.

Basis Report does not hold positions in securities discussed. This is not investment advice.